3.29

0.60% -0.02

After Hours: 3.18 -0.11 -3.34%

Cabaletta Bio Inc (CABA)

Overview News Price History Option Chain Financials Why CABA Down? Discussions Forecast

Cabaletta Bio Inc stock is traded at $3.29, with a volume of 2.73M. It is down -0.60% in the last 24 hours and down -4.36% over the past month. Cabaletta Bio Inc is a late clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. Its proprietary Cabaletta Approach to B cell Ablation (CABA) platform includes the CARTA approach, which uses chimeric antigen receptor T cells to eliminate B cells and potentially reset the immune system. The company develops cellular therapies including CAR T and CAAR T product candidates. Its candidate, rese-cel (resecabtagene autoleucel), a CD19-CAR T cell therapy, is being evaluated in Phase 1/2 trials for autoimmune diseases such as systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris.

Previous Close:

$3.31

Open:

$3.3

24h Volume:

2.73M

Relative Volume:

0.87

Market Cap:

$536.45M

Revenue:

Net Income/Loss:

$-167.86M

P/E Ratio:

-1.4345

EPS:

-2.2935

Net Cash Flow:

$-132.31M

1W Performance:

-13.87%

1M Performance:

-4.36%

6M Performance:

+40.60%

1Y Performance:

+62.07%

1-Day Range:

$3.18

$3.32

1-Week Range:

$3.18

$3.865

52-Week Range:

$1.26

$4.23

Cabaletta Bio Inc Stock (CABA) Company Profile

Name

Cabaletta Bio Inc

Sector

Healthcare (1109)

Industry

Biotechnology (612)

Phone

(267) 759-3100

Address

2929 ARCH STREET, PHILADELPHIA, PA

Employee

158

Twitter

@CabalettaBio

Next Earnings Date

2026-05-21

Latest SEC Filings

CABA's Discussions on Twitter

Compare CABA vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CABA Cabaletta Bio Inc	3.29	539.71M	0	-167.86M	-132.31M	-2.2935
VRTX Vertex Pharmaceuticals Inc	436.58	110.90B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	629.68	73.20B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	776.26	49.71B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	286.27	38.32B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	144.37	30.97B	742.00K	-1.37B	-1.07B	-7.0731

Cabaletta Bio Inc Stock (CABA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-10-25	Resumed	Jefferies	Buy
Dec-20-24	Downgrade	Evercore ISI	Outperform → In-line
Dec-19-24	Downgrade	Wells Fargo	Overweight → Equal Weight
Oct-10-24	Initiated	UBS	Buy
Feb-05-24	Initiated	Jefferies	Buy
Nov-29-23	Initiated	William Blair	Outperform
Oct-24-23	Initiated	Cantor Fitzgerald	Overweight
Oct-19-23	Initiated	Stifel	Buy
Sep-05-23	Initiated	Citigroup	Buy
Jul-18-23	Initiated	Guggenheim	Buy
Jan-27-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Aug-30-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Dec-08-21	Initiated	Wells Fargo	Overweight
Oct-19-21	Resumed	Morgan Stanley	Overweight
Jun-30-21	Initiated	Mizuho	Buy
Jan-08-21	Initiated	Chardan Capital Markets	Buy
Oct-13-20	Initiated	H.C. Wainwright	Buy
Nov-19-19	Initiated	Cowen	Outperform
Nov-19-19	Initiated	Evercore ISI	Outperform
Nov-19-19	Initiated	Morgan Stanley	Overweight

View All

Cabaletta Bio Inc Stock (CABA) Latest News

03:01 AM

Cabaletta Bio (CABA) upgraded to buy: Here's why - MSN

03:01 AM

01:17 AM

Cabaletta Bio (CABA) Upgraded to Buy: Here's Why - sharewise.com

01:17 AM

May 15, 2026

Guggenheim Maintains Cabaletta Bio(CABA.US) With Buy Rating, Maintains Target Price $16 - Moomoo

May 15, 2026